Ralf Clemens
Director/Board Member at CLOVER BIOPHARMACEUTICALS, LTD.
Net worth: 30 324 $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ingmar Hoerr | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 21 years |
Florian von der Muelbe | M | 52 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 24 years |
Christophe Weber | M | 57 | 10 years | |
Friedrich von Bohlen und Halbach | M | 60 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Michael Brosnan | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 years |
Baron Jean Stéphenne | M | 73 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
Andrew Plump | M | 58 | 9 years | |
Constantine Saroukos | M | 53 | 9 years | |
Xiang Liao | M | 59 | 3 years | |
Thomas Leggett | M | 47 | 3 years | |
Frédéric Jacotot | M | 60 | 7 years | |
Mathias Hothum | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
Timothy M. Wright | M | 69 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 6 years |
Debra Stephanie Barker | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 years |
Igor Splawski | M | 56 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 4 years |
Xiao Bin Wu | M | 62 | 3 years | |
Joshua Liang | M | - | 4 years | |
Pierre Kemula | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 8 years |
Hans Tanner | M | 72 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 9 years |
Christian Mandl | M | - |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 6 years |
Aileen Wang | F | - | 3 years | |
Jeffrey Farrow | M | 62 | 3 years | |
Bernd Winterhalter | M | 65 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
Craig Tooman | M | 58 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 5 years |
Mariola Fotin-Mleczek | M | 50 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 18 years |
Peng Liang | M | 63 | 6 years | |
Adel Mahmoud | M | 82 |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | - |
Htay Htay Han | F | 56 | 3 years | |
Xiao Bing Li | M | 56 | 4 years | |
Lindiwe Majele Sibanda | M | 61 |
African Research Excellence Fund
| - |
Liong Ho Chua | M | 60 | 2 years | |
Lily Yang | F | - | 3 years | |
Myriam Mendila | M | 58 | 1 years | |
Malte Greune | M | 59 | 3 years | |
Hing Ling Chau | F | 49 | 3 years | |
Viola Bronsema | M | 61 | 4 years | |
Jean Stephenne | M | 75 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | - |
Ulrike Gnad-Vogt | M | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 13 years |
George Bickerstaff | M | 68 |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 15 years |
Jerome H. Kim | M | - |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 9 years |
Fred Binka | M | - |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 11 years |
Alexander Zehnder | M | 54 | 1 years | |
Donna Ambrosino | M | 72 | 2 years | |
Xiao Dong Wang | M | 61 | 3 years | |
George Siber | M | 79 |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 11 years |
J. Kim | M | 55 |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 11 years |
Klaus Schollmeier | M | 67 | 2 years | |
Wang Xiaoyan | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Iwaaki Taniguchi | M | - | - | |
Shiro Kuniya | M | 67 | - | |
François-Xavier Roger | M | 62 | 2 years | |
Sandra E. Poole | F | 60 | 3 years | |
Deborah Dunsire | M | 61 | 3 years | |
Brian Krex | M | 57 | 2 years | |
Michel Gréco | M | 80 | 4 years | |
Frank Morich | M | 69 | 4 years | |
Masahiro Sakane | M | 83 | - | |
Hans Lennart Rudolf Wigzell | M | 86 | 3 years | |
Phillip Eric Lee | M | 37 | 1 years | |
Timothy Sullivan | M | 54 | 3 years | |
Kirsten Detrick | F | 59 |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The company is based in Deerfield, IL. | - |
Louisa Shaw-Marotto | F | 56 | 4 years | |
Claudio Dansky Ullmann | M | - | 3 years | |
Wolfgang Bender | M | 70 | 3 years | |
Marina Rubini | F | 55 |
Novartis Vaccines & Diagnostics Srl
| 2 years |
Dong Lyu | M | 49 | 1 years | |
Klaus Edvardsen | M | 62 | 1 years | |
Yan Zhu | M | 60 | 2 years | |
Frédéric Legros | M | 48 | - | |
Azmi Nabulsi | M | 64 | 4 years | |
Dimitris Voliotis | M | 61 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 1 years |
Antony Blanc | M | 57 | 3 years | |
Michael Vasconcelles | M | 61 |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The company is based in Deerfield, IL. | 3 years |
Satoshi Adachi | M | - | - | |
Asit Parikh | M | 52 | 7 years | |
Hiromichi Kimura | M | 73 | 7 years | |
Anna Protopapas | F | 59 | 4 years | |
David Lawrence | M | 61 | - | |
Daniel L. Menichella | M | 64 |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | 2 years |
Reinhard Kandera | M | 54 | 4 years | |
Michael Martin | M | 50 | 3 years | |
Franz-Werner Haas | M | 54 | 11 years | |
Masato Iwasaki | M | 65 |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The company is based in Deerfield, IL. | - |
Mette Vinge | F | - |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The company is based in Deerfield, IL. | 2 years |
Trevor Smith | M | - | - | |
Jostein Davidsen | M | 65 | 3 years | |
Karen Ferrante | M | 66 | 6 years | |
Tetsuo Miwa | M | - | - | |
Futoshi Sanematsu | M | - | - | |
Bali Muralidhar | M | 44 | 2 years | |
An Bang Lu | M | 58 | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Germany | 26 | 28.57% |
Japan | 24 | 26.37% |
China | 18 | 19.78% |
France | 10 | 10.99% |
South Korea | 7 | 7.69% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ralf Clemens
- Personal Network